Skip to main content

ET-105 FDA Approval Status

Last updated by Judith Stewart, BPharm on Aug 13, 2019.

FDA Approved: No
Brand name: ET-105
Generic name: lamotrigine
Company: Eton Pharmaceuticals, Inc.

ET-105 is an oral liquid formulation of lamotrigine in development as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.

Development timeline for ET-105

Feb 19, 2020Eton Pharmaceuticals Provides Update on ET-105 Program
Aug  1, 2019Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.